Method for treating chlamydiosis in calves
FIELD: veterinary science.
SUBSTANCE: the method deals with injecting oxylate once daily for 3 d at the dosage of 1 ml/30 kg body weight at repeated therapy course in 5 d at the background of antibioticotherapy. The method enables to normalize biochemical and morphological blood values and increase average daily body weight gain in sick animals.
EFFECT: higher efficiency of therapy.
2 ex, 2 tbl
The invention relates to veterinary medicine, in particular to a method of treatment of chlamydia calves.
There is a method of treatment with tetracycline antibiotics, namely oxytetracycline (Chlamydia farm animals. - M.: Kolos, 1984. - S).
The disadvantages of this method of treatment can be considered one-way causal influence on the organism of the animal, the possible development of dysbacteriosis and secondary immunodeficiency.
There is a method of treatment of feed antibiotics: biovet - 40, 80, 120 (Biology and environmental problems of infectious diseases of wild animals and their role in the pathology of farm animals and people. (Materials of the International scientifically-practical conference. - Cover. 2002. - S).
This method is based on monotherapy and eliminates the use of immunocorrective drugs that improve treatment efficacy and reduce side effects of antibacterial drugs.
The technical problem solved by the invention consists in the extension of the treatment of chlamydia.
The invention consists in that for the treatment for chlamydia calves used drug oxalat (RF patent No. 2076702, THE 9336-02-16923913-00) on the background of antibiotic drugs tetracycline group.
With this method of treatment using Biovit - 80 in d is se 6 g per head, with morning and evening feeding of milk, for 7-10 days and oxalat by subcutaneous injection once a day for 3 days, at a dose of 1 ml/30 kg body weight. Treatment oxylator repeated after five days. The use of this method of treatment improves the efficiency of treatment by 20%, increase average daily weight gain of animals affected by 29.9%.
In experiments to study the effectiveness of treatment used calves postnatal period, with clinical signs of gastroenterocolitis, which by polymerase chain reaction in the scrapings of the mucous membrane of the rectum and blood samples allocated DNA of chlamydia. To assess the effectiveness of treatment before conducting experiments and 10 days after treatment was performed morphological and biochemical blood tests, was determined lysozime, bactericidal and macrophage activity, 2 months - took samples for DNA extraction chlamydia by PCR using the test-system “Glocom”.
Example 1. The experience was 15 calves, patients with chlamydia. The calves of the first group (5 animals) used Biovit - 80 at a dose of 6 g per head, with a morning and evening feeding of milk, for 7-10 days and oxalat by subcutaneous injection once a day for 3 days, at a dose of 1 ml/30 kg body weight. After five days treatment with oxylator repeated.
Calves second GRU the dust was fed to Biovit - 80 at a dose of 6 g per head, with a morning and evening feeding of milk, for 7-10 days.
Animals of the third group (5 animals) treated by oxylator by subcutaneous injection once a day for 3 days, at a dose of 1 ml/30 kg body weight. After five days the treatment was repeated.
After treatment of the DNA of chlamydia isolated from one calf of the first group, two second and three third. Safety in all groups was 100%. Clinical signs (diarrhea) remained one of the calves treated with biovita - 80. Average daily weight gain in calves the first group amounted to 633 g, the second group 344 g, third - 540, the Effectiveness of the treatment in the first group was 80%, the second is 60%, in the third to 40%. Data reflecting the effectiveness of the treatment, are presented in table 1.
Example 2. Calves from the experimental group, patients with chlamydia, with signs of gastrointestinal tract (5 goals), was used nicox-200 as a deep intramuscular injection at a dose of 1 ml/10 kg of body weight, once and oxalat by subcutaneous injection once a day for 3 days, at a dose of 1 ml/30 kg body weight. After five days treatment with oxylator repeated.
The calves of the control group, with signs of gastrointestinal tract (5 goals), was used nicox - 200 as a deep intramuscular injection at a dose of 1 ml/10 kg of body weight, onocr the IDT.
After treatment of the DNA of chlamydia isolated from one calf from the experimental group, two - control. Safety in groups was 100%. Clinical signs of diarrhoea after treatment were noted. Average daily weight gain in calves from the experimental group amounted to 485 g, control 610, the effectiveness of the treatment in the experimental group was 80%control 60%. Data reflecting the effectiveness of the treatment, are presented in table 2.
According to the results of laboratory studies, the level of red blood cells in calves of all groups were consistent with physiological norm and did not differ significantly. The number of cells on the 10th day after treatment was increased by 18,67% in calves of the first group, 11,72% calves third and 16,67% in animals exposed to treatment Nicolson. The amount of hemoglobin was significantly increased in calves of most groups. The exception was the animals, which was used nicox. The indicator in this case declined to 7.64% and amounted to 98,99±of 7.48 g/L. At the same time, in calves, which used complex nitox/oxalat, the indicator has not changed and amounted to 102,45±2.20 g/L. In the same group in calves increased levels of circulating immune complexes: 7,69%. In calves the third group, this indicator increased by 38,67%. At the same time in the blood samples of calves of these groups increased the authors estimated the effect activity. In calves, which were used only nor the ACS and Biovit, FOREPLAY decreased by 43,81% and 34.6%, respectively. BASK decreased in animals of all groups. Macrophage activity was increased in all calves, but also increasingly subjected to comprehensive treatment oxalat/Biovit (32,15%) and amounted to 48,42%.
Thus, the use of oxalate by subcutaneous injection once a day for 3 days, at a dose of 1 ml/30 kg body weight with repeat treatment after five days and biovita - 80 at a dose of 6 g per head, with a morning and evening feeding of milk within 7-10 days promotes recovery calves and elimination of the pathogen chlamydia in 80% of cases.
The application of this method of treatment can improve the economic efficiency of treatment by 20% compared with traditional schemes monotherapy antibiotics, helps to normalize biochemical and morphological parameters of blood, increase average daily weight gain of infected animals, on average, 187,
The treatment for chlamydia calves with clinical signs of gastroenterocolitis, including the use of the drug, characterized in that the quality of drug use oxalat, which is injected once a day for 3 days, at a dose of 1 ml/30 kg body weight with a repetition rate of treatment oxylator through p is th days on the background of antibiotic therapy.
FIELD: organic synthesis.
SUBSTANCE: invention provides substituted 7-acylaminocephalosporins of formula I:
(I), where W denotes CH or B; V denotes NO; R1 hydrogen or С1-С4-alkyl; R3 hydrogen or ester residue; and R2 one of the following groups: , , , , in which X, R5, R6, R'6, R7, and Hal have meanings indicated in claims, in free state, in the form of salts and/or solvates, or, if such forms are stable, in the form of internal salt, quaternary salt, or their hydrates, possessing antimicrobial activity. Invention also discloses a method for preparing such compounds and a pharmaceutical connected containing them.
EFFECT: increased choice of antimicrobial preparations.
13 cl, 10 tbl, 225 ex
SUBSTANCE: composition is constituted by effective amount of thymol obtained from plant Trychyspermum ammi, mint oil combination of mint oil containing required amounts of monoterpenes and isolated from Mentha spicata and Mentha arvensis, and typical additives. Invention also relates to preparation of the composition by mixing above ingredients and to method of treating patients by administering therapeutically effective amount of the composition.
EFFECT: created therapeutic agent overcoming drug resistance of bacteria and minimized or even eliminated secondary adverse effect of drug.
19 cl, 12 tbl, 11 ex
FIELD: pharmacology, fluorinated quinolone-based drug, in particular ofloxacine for injections.
SUBSTANCE: claimed composition contains therapeutically acceptable amount of ofloxacine and trilon-B, sodium chloride, water for injections as additives.
EFFECT: high therapeutic effectiveness; non-crystallized active agent for a long-time storage.
FIELD: biotechnology, medicine, infectious diseases, medicinal microbiology.
SUBSTANCE: invention relates to a composition designated for treatment and prophylaxis of infections caused by Neisseria microorganism that comprises the following components: (a) protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of a single species (the first group of amino acid sequences is given in the text) and/or its fragment consisting of 10 and more amino acids and eliciting antigen properties; (b) the second protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of another species (the second group of amino acid sequences with even numbers is given in the text), and/or its fragment consisting of 10 or more amino acids and eliciting antigen properties; in particular, the second protein represents NspA. The composition comprises additionally adjuvant. The composition is used both a medicinal agent and for manufacturing the medicinal agent. Applying the invention provides enhancing the effectiveness of prophylaxis or treatment due to the universal effect of the composition (vaccine). Invention can be used in medicine for treatment of infections.
EFFECT: valuable medicinal properties of composition.
8 cl, 137 dwg, 5 tbl, 12 ex
SUBSTANCE: before applying substitute hormonal therapy (SHT) on should evaluate antithrombogenic activity of vascular wall in women. For this purpose one should determine quantitative values of ADP-induced aggregation of thrombocytes, activity of antithrombin III in blood and fibrinolytic blood activity both before and after "cuff"-test. Then one should detect the indices calculated as the ratio of mentioned values both before and after carrying out the mentioned test. If mentioned indices are decreased against the norm by 20-40% women should be prescribed to undergo SHT at additional introduction of aspirin and supradin. The method provides prophylaxis of cardio-vascular diseases in this category of female patients due to correcting affected functional activity of vascular endothelium.
EFFECT: higher efficiency of prophylaxis.
1 cl, 1 ex, 4 tbl
FIELD: organic chemistry, pharmacy.
SUBSTANCE: invention relates to new derivatives of dihydropyrimidine of the general formula (I):
or its isomeric form of the formula (Ia):
that can be used, for example, for treatment and prophylaxis of hepatitis B. In indicated formulas R1 means unsubstituted phenyl or phenyl substituted once or many times with similar or different substitutes taken among the group including halogen atom, trifluoromethyl group, nitro-, amino-group, hydroxyl and alkyl with 1-6 carbon atoms, or residues of formulas:
, or ; R2 means residue of the formula -XR5 wherein X means a bond or oxygen atom; R5 means alkenyl with 2-4 carbon atoms or alkyl with 1-4 carbon atoms that can be unsubstituted or substituted with phenoxy-group; R3 means amino-group, alkyl with 1-4 carbon atoms or cyclopropyl; R4 means pyridyl that is substituted with up to three times with similar or different substitutes taken among the group including halogen atom, trifluoromethyl group, alkoxy-group with 1-6 carbon atoms and alkyl with 1-6 carbon atoms, and their salts. Also, invention relates to 3,5-difluoro-2-pyridincarboxyimidamide and 3,5-difluoro-2-pyridincarbonitrile that can be sued as intermediates products for preparing compounds of the formula (I) or (Ia) and to a medicinal gent.
EFFECT: improved preparing method, valuable medicinal properties of compounds.
10 cl, 2 sch, 4 tbl, 9 ex
FIELD: organic chemistry, chemical technology, medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to new derivatives of sulfonamides of the formula (I) or their pharmaceutically acceptable salts wherein R1 means -OH or -NHOH; R2 means hydrogen atom; R3 means alkyl, alkoxyalkyl, arylalkyl, pyridylalkyl or morpholinylalkyl; A means piperidyl or tetrahydrofuranyl; n = 0; E means a covalent bond; (C1-C4)-alkylene, -C(=O)-, -C(=O)O- or -SO2-; X means hydrogen atom, alkyl, aryl, arylalkyl, alkoxyalkyl, morpholinyl or tetrahydropyranyl; each among G and G' means -C(R5)=C(R5') wherein R5 and R5' mean hydrogen atom; M means the group -CH-; z means the group -(CR7R7')a-L-R8 wherein a = 0 and each among R7 and R7' means hydrogen atom; L means a covalent bond; R8 means halogen atom or alkoxy-group. Compounds of the formula (I) are inhibitors of metalloproteases and can be used for treatment of arthritis, cancer tumors and other diseases.
EFFECT: valuable medicinal properties of compounds.
15 cl, 7 tbl, 56 ex
FIELD: organic synthesis.
SUBSTANCE: invention provides compounds of general formula I:
, where R1 represents -CO-Ra, -SO2-Rb, or aryl optionally substituted by lower alkoxy, wherein Ra represents cycloalkyl, cycloalkyl(lower)alkyl, cycloalkyloxy, aryl, aryloxy, aryl(lower)alkyl, aryl(lower)alkoxy, aryloxy(lower)alkyl, aryl-S-(lower)alkyl, aryl(lower)alkenyl, provided that aryl group can be optionally substituted by halogen, lower alkyl, hydroxy, nitro, cyano, lower alkoxy, phenyl, CF3, cyano(lower)alkyl, lower alkyl-C(O)NH, lower alkyl-CO, and lower alkyl-S; heteroaryl, heteroaryl(lower)alkyl, or heteroaryl(lower)alkoxy, provided that heteroaryl group is 5- or 6-membered ring or bicyclic aromatic group constituted by two 5- or 6-membered rings including 1-3 heteroatoms selected from oxygen, nitrogen, and sulfur and that heteroaryl group can be optionally substituted by lower alkoxy; Rb represents aryl, aryl(lower)alkyl, or heteroaryl, aryl group optionally substituted by halogen, cyano, or lower alkyl-C(O)NH; R2 and R3 represent hydrogen atoms; R4 representshydrogen or lower alkyl; R5 represents hydrogen, lower alkyl, cycloalkyl, benzodioxyl, or aryl optionally substituted by lower alkyl, halogen, lower alkoxy, hydroxy, or (lower)alkyl-C(O)O; n is 1 or 2; and pharmaceutically acceptable salts thereof and/or pharmaceutically acceptable esters thereof. Invention also provides a pharmaceutical composition exhibiting inhibitory activity with regard to cysteine proteases of the cathepsin family, which composition comprises compound of formula I, pharmaceutically acceptable recipient, and/or adjuvant.
EFFECT: increased choice of cysteine protease inhibitors.
34 cl, 1 tbl, 13 ex
FIELD: medicine, surgery.
SUBSTANCE: at the background of basic therapy in complex therapy of acute pancreatitis one should introduce ceruloplasmin to be applied at the dosage of 600-1000 mg/d for 5 d. If necessary, the course of ceruloplasmin introduction should be repeated. This method provides pancreatic tissues viability in case of pancreonecrosis by increasing efficiency of correction the endogenous intoxication and decreasing the number of complications in the course of therapy conducted.
EFFECT: higher efficiency of pharmacological correction.
SUBSTANCE: the present innovation deals wit treating and preventing skin diseases. One should treat the focal surface with the ointment based upon an antiseptic Dorogov's stimulant followed by intravenous injections of sodium thiosulfate solution and restorative therapy. Moreover, this ointment contains birch oil, ichthyol and lubricant grease. As restorative therapy one should prescribe the tincture of medicinal plants species. This method provides more stable remission.
EFFECT: higher efficiency of therapy.
1 cl, 2 ex
SUBSTANCE: method involves introducing endoscope, clearing injured surface and applying gel produced on Tisol substance base (aqua-complex of titanium glycerosolvate) as medicinal composition via the endoscope. Tisol is administered as aqueous solution of concentration not less than 60% after Tisol. The composition is applied to injured surface in the amount of 2 to 8 ml for one session. The number of treatment sessions is equal to 1 to 7 with 3-5 days long pauses. The composition is prepared by mechanically mixing medicinal microadditives with Tisol substance. The medicinal microadditives are introduced in total amount of 7.26% of composition mass. The ingredients are selected depending on disease. The medicinal composition is applied as 1-2 mm thick layer. When treating the cases of erosion or gastritis, sea-buckthorn oil and/or propolis solution are of preference to be introduced into Thysol as the medicinal microadditives. When treating the cases of gastric or duodenal peptic ulcer, methyluracyl, hydrocortisone, cycloferon or aecol are preferentially introduced into Tisol as the medicinal microadditives. The composition formula is adjusted from session to session on the basis of treatment results visual control and analysis data. Taking meals and drinks is restricted for a patient for half an hour or longer.
EFFECT: enhanced effectiveness in administering drugs into mucous membrane and soft tissues without using needle injectors.
5 cl,4 tbl
FIELD: chemical and pharmaceutical industry.
SUBSTANCE: the present innovation deals with creating medicinal preparations of plant origin and could be applied for treating functional constipations and affected biorhythm of defecation. It is suggested to apply either dry aqueous or aqueous-alcoholic extract of horse chestnut seeds of Aesculus species to prepare curative-prophylactic preparation in case of constipation and affected biorhythm of defecation. The suggested preparation should be applied in the form of powder, tablets or suppositories. Pharmaceutical composition for preventing and treating constipation and affected biorhythm of defecation contains an active substance out of medicinal plant and a pharmaceutically acceptable filling agent, moreover, this preparation is designed as suppositories and contains either dry aqueous or aqueous-alcoholic extract of horse chestnut seeds of Aesculus species and suppository hydrophobic foundation at certain content of ingredients. Dry aqueous or aqueous-alcoholic extract contains 1-50% active substance as escin. As foundation it could contain either cacao oil or vitepsol. The method for preventing and treating constipations and affected biorhythm of defecation deals with introducing the suggested pharmaceutical composition into patient's anus 5-15 min before planned act of defecation. Application of "Rectum-activ" preparation provides positive result at treating functional psychogenic constipation: in 5-15 min after introducing a suppository into anus pronounced urgency for defecation. In case of course therapy for 4 wk one should observe restoration of natural urgency for intestinal evacuation. Moreover, purgative preparation causes no unfavorable pain feelings.
EFFECT: higher efficiency.
10 cl, 6 ex
FIELD: medicine, surgical gastroenterology.
SUBSTANCE: as a curative preparation one should apply a pectin-containing powder product of table beet out of sublimated raw material. For reducing the powder before application one should apply low-mineralized low-alkaline amicrobial solution of electrochemically activated catholyte. Supernatant transparent fraction of this solution should be constantly introduced by drops into nasobiliary probe, residual fraction should be applied for peroral additional enterosorption. The method provides sanitation of biliary ducts by preventing duodenocholedochous reflux, and enterosorption that decreases portal toxemia.
EFFECT: higher efficiency of therapy.
2 cl, 1 ex
FIELD: medicine, gastroenterology.
SUBSTANCE: one should apply food additives as tablets of oats, corn and cabbage by "Biophyt" company; moreover, to decrease motor system of biliary ducts one should apply tablets of oats, to increase motor system - tablets of corn and for total normalization of kinetics - tablets of cabbage. Treatment lasts for 10 d at the dosage of 1-2 tablets twice daily 30 min meals. The present innovation enables to normalize functional activity of biliary ducts at the background of shortened therapeutic terms.
EFFECT: higher efficiency of therapy.
FIELD: medicine, gastroenterology, phytotherapy, pharmacy.
SUBSTANCE: invention relates to solid medicinal formulations, namely capsules "Gastrobiol-TSD". Gelatin capsule contain the natural pharmacologically active component - sea-buckthorn oil concentrate, cyclodextrin, vitamin U and magnesium oxide taken in the definite ratio of components given in the invention description. Invention provides preparing a medicinal formulation eliciting an anti-ulcer, analgetic and protective effect on mucosa effect being with minimal risk for development of adverse effect.
EFFECT: valuable medicinal properties of preparation.
1 tbl, 1 ex